Deviating from radiation protocols increases risk of treatment failure and death

October 30, 2012

Implementing measures to ensure radiation therapy protocols are followed not only decreases deviations, but it can also improve overall survival in cancer patients, Thomas Jefferson University Hospital researchers suggest in a first-of-its kind study presented during a plenary session at the American Society for Radiation Oncology (ASTRO) 54th Annual Meeting in Boston.

Researchers from the Department of Radiation Oncology at Jefferson analyzed radiation therapy protocols, quality assurance (QA) measures and patient outcomes in eight, large clinical trials to determine if such deviations were associated with inferior clinical outcomes.

The findings, presented by Nitin Ohri, M.D., who conducted the research while at Jefferson, but is currently at Albert Einstein/Montefiore Medical Center in New York., revealed that deviating from protocols was associated with up to a 75 percent increased risk of and overall mortality. This suggests that implementing QA measures to ensure protocols are followed could improve outcomes for cancer patients, according to the authors.

It is widely accepted that deviating from a radiation therapy protocol in a clinical trial will more than likely result in adverse effects. And, as a result, significant QA measures have been taken over the last several decades to minimize such effects. However, while these measures have shown to decrease deviation, there is currently no data establishing the patient-outcome benefits of those measures. This is the first study, to the author's knowledge, to examine the effects on those measures on risk of treatment failures and mortality.

Examples of radiation therapy deviation include inadequate targeting of high-risk lymph node regions or incorrect dose calculation.

Other authors of the study include Adam P. Dicker, M.D., Ph.D., Chair of the Department of at Jefferson and the Kimmel Cancer Center at Jefferson, Laura Doyle, M.S., and Amy Harrison, M.S., of Jefferson's Department of Radiation Oncology, and Timothy Showalter, M.D., and Xinglei Shen, M.D.

The researchers examined two lung cancer trials, three trials for medulloblastoma, and trials for Ewing's sarcoma, pancreatic cancer and head and neck cancer, which included over 2,000 patients in total. They extracted information from the clinical trials, including number of patients included in QA analysis, definition of radiotherapy protocol deviation, and number of patients with and without radiotherapy deviations.

The frequency of radiation therapy deviations, they found, ranged from 8 percent to 71 percent. Those deviations were also associated with a significant decrease in overall survival, and with an approximately 75 percent increase in the risk of treatment failure and mortality.

"The magnitude of these effect sizes demonstrates that delivery of high-quality and having a rigorous QA program is critical for the successful execution of clinical trials and for the effective treatment of all cancer patients," said Dr. Dicker. "With such practices, deviations decrease and thus overall survival rates for cancer patients improve."

Explore further: Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival

Related Stories

Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival

January 12, 2012
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind ...

Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy

April 13, 2011
A widely-available yet expensive radiotherapy technique used to treat prostate cancer patients after surgery has promising benefits -- higher dose and less damage to the rectum and bladder -- compared to a less precise technique, ...

Brachytherapy reduced death rates in high-risk prostate cancer patients, study finds

January 25, 2012
Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. A population-based ...

Emerging trends in radiation therapy for women over 70 with early stage breast cancer

June 2, 2011
Patterns of radiation usage in breast conserving therapy for women 70 years and older with stage I breast cancer are changing: more women are opting for radioactive implants and those with estrogen positive tumors are opting ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.